Most Recent
Novartis patent for oral form of top-selling MS drug obvious, IP Australia says
Intellectual Property May 13, 2019 12:31 pm By Miklos Bolza

A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has […]

Subscribe for instant access to all Lawyerly content. Already a subscriber? Login here. Want to test drive Lawyerly? Contact us to take a free trial.
Juno Pharmaceuticals settles trade mark dispute with Juno Therapeutics
Intellectual Property January 25, 2019 3:42 pm By Miklos Bolza

Juno Pharmaceuticals has resolved its appeal of an IP Australia ruling that allowed Seattle-based Juno Therapeutics to extend protection of its namesake trade mark into […]

Subscribe for instant access to all Lawyerly content. Already a subscriber? Login here. Want to test drive Lawyerly? Contact us to take a free trial.